R&D
Biomedical researchers discuss results

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.

Market Access
nine for 2023

Nine for 2023, part three: thriving or surviving?

In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D

R&D
Biomedical researchers discuss results

The reasoning problem

In R&D, decisions that matter most rarely happen during the documented steps; they happen in the pauses between them.